Alto Neuroscience to Present at the TD Cowen 44th Annual Healthcare Conference

Published

LOS ALTOS, Calif.--(BUSINESS WIRE)-- Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced that Amit Etkin, M.D., Ph.D., founder and chief executive officer, will present a company overview at the TD Cowen 44th Annual Healthcare Conference on Tuesday, March 5, 2024, at 1:30 pm ET.

The presentation will also be available via live webcast on the Events and Presentations page in the Investors section of Alto’s website and a replay will be available for 90 days following the presentation.

About Alto Neuroscience

Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Alto’s Precision Psychiatry Platform™ measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to better identify which patients are more likely to respond to Alto product candidates. Alto’s clinical-stage pipeline includes novel drug candidates in depression, PTSD, schizophrenia, and other mental health conditions. For more information, visit www.altoneuroscience.com or follow Alto on X.

Investor Contact: Nick Smith investors@altoneuroscience.com

Media Contact: Jordann Merkert media@altoneuroscience.com

Source: Alto Neuroscience, Inc.

In This Story

ANRO